The aim of this single centre prospective open trial was to evaluate the long-term efficacy of octreotide LAR in acromegaly patients and possibility of withdrawal of this therapy.
In total 17 patients with acromegaly diagnosed at Endocrinology Clinic in Sarajevo, somatostatin sensitive (10 females and 6 males, age range 37-65 years, 6 patients with microadenoma and 10 patients with macroadenoma) were treated with octreotide LAR. Follow-up period was 4 years (2009) (2010) (2011) (2012) (2013) (2014) . Ten patients were treated with surgical and octreotide treatment. One patient was treated with surgical, octreotide and gamma-knife treatment and six patients were treated only with octreotide LAR. The concentration of human Growth Hormone (hGH) and Insulin-Like Growth Factor I (IGF-1) were evaluated before treatment and every 6 months during follow-up period of 4 years, while magnetic resonance imaging (MRI) was taken before the treatment and every year during follow-up period. 
Objective

Methods
Results
During the first year of treatment 10 patients were included. In the second year a further seven patients were involved. At one patient treatment was successful discontinued without subsequent recurrence during follow-up. After 2 years, at another 2 patients treatment was off because well-controlled acromegaly, one patient was died due to co-morbidities and at one another patients treatment was off due to kidney cancer. After 3 years of treatment one of patient must be subjected to gamma-knife treatment followed by continued treatment with 30 mg of octreotide LAR and at one patient the dose was increased up to 60 mg. During the fourth year of follow-up, the treatment was successful discontinued at another one patient, so currently we followed total of 11 patients; 8 of them used therapy for 4 years and 3 of them used therapy for 3 years. During follow-up period octreotide LAR treatment significantly reduced GH (50.87 ± 10.56 vs 2 ± 0.36 ng/ml, p<0,005), IGF-1 (777.66 ± 118.40 vs 276 ± 80.54 ng/ml, p<0,005) and adenoma size (from 9,6 to 6 mm; p<0,01). After therapy, a GH decrease to less than 2.5 ng/ml was achieved in 82% of cases; tumor size decrease was achieved in 60% while normalization of IGF-1 was achieved in 91% of the patients, respectively. At 12-24 months of follow-up, 23,5% of somatostatin sensitive acromegaly patients had withdrawn treatment, without recurrence.
Conclusion
Our findings demonstrated that octreotide LAR treatment is very effective in decrease of GH, IGF-1 and tumor size and their withdrawal, though rare, is possible in well-selected acromegalic patients treated for at least 2 years and considered optimally controlled in hormonal and neuroradiological terms. 
